ICER #WeeklyView: The most important ICER stories of 2025 conta.cc/3MDt6q0

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatments for Obesity: tinyurl.com/nd8y5kvv

ICER #WeeklyView: Smoking cessation Evidence Report, IgAN Draft Evidence Report & rising prescription drug costs conta.cc/4pX81Fg

Institute for Clinical and Economic Review Publishes Evidence Report on Medication for Smoking Cessation: tinyurl.com/5xuk6pza

Institute for Clinical and Economic Review Releases Draft Evidence Report on Therapies for IgA Nephropathy: tinyurl.com/ycyva2tr

ICER #WeeklyView: ICER CEO on RHV Podcast, Medicare negotiated prices, & PBM alternatives emerge conta.cc/3Mfy4ZP

ICER President and CEO Sarah K. Emond joined the @relentleshealth.bsky.social pod to discuss the tensions that exist in drug pricing and how paying for value can help fix them. Listen: cc-lnk.com/EP494. The bonus episode talks about ICER's work and more: cc-lnk.com/EP494-BonusC....

This week ICER marks the 5-year anniversary of ICER Analytics™, our cloud-based platform that has revolutionized the ability of users to develop formularies, negotiate drug prices, and explore new ways to apply ICER’s evidence. Learn more at analytics.icer.org.

ICER #WeeklyView: ICER Analytics is 5, ICER interviewed on GLP-1 pricing, & health benefits costs to increase conta.cc/4ieQnKC

ICER #WeeklyView: This holiday season, consider donating to ICER conta.cc/4oMsVXK

Institute for Clinical and Economic Review Releases Draft Scope on Vaccines for Covid-19: tinyurl.com/4enrmhsf

ICER #WeeklyView: Obesity public meeting, paying for value for obesity meds, & responses to ICER’s Launch Price and Access Report conta.cc/4nLPYAy

ICER #WeeklyView: NCFB and obesity Evidence Reports, Cigna ends rebates, & updated approval for biosimilars conta.cc/4oIRkg6

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/4rmnz269

Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Obesity: tinyurl.com/3wbemnr9

Today: Join ICER for a conversation around rising launch prices, and the implications for affordability and patient access. Register for the 2025 Launch Price and Access Report: Policy Implications webinar: tinyurl.com/3xukfka2

ICER #WeeklyView: Launch Price and Access Report and webinar, & assessments for narcolepsy and smoking cessation conta.cc/4nhUsP2

New Institute for Clinical and Economic Review Report Shows Significant Jump in Launch Prices, Exceeding Inflation and GDP Growth: tinyurl.com/46swvktj

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Smoking Cessation: tinyurl.com/3c9n6bkh

Institute for Clinical and Economic Review to Assess Treatment for Narcolepsy: tinyurl.com/2vw57seu

ICER #WeeklyView: Launch Price and Access Report webinar, On Point interview, & California PBM reforms conta.cc/47fZHsJ

ICER #WeeklyView: HEMA Draft Report, ICER’s paper in Health Affairs Scholar, & the Colorado PDAP vote conta.cc/3KIpfXJ

Health Economics Methods Advisory Group Releases Draft Report: Assessing Treatment Benefits in HTA Decision-Making tinyurl.com/yc47dejv

How to make one line in the FDA Commissioner’s new drug review program into a force for affordable access for patients -- a new Health Affairs Scholar paper by ICER President and CEO Sarah Emond and Chief Scientific Officer Dan Ollendorf: tinyurl.com/32bexcd9

ICER #WeeklyView: Vaccines for COVID-19 to be assessed, Trump Administration’s drug pricing announcements, & ACA subsidies conta.cc/4nCjZDy

Institute for Clinical and Economic Review to Assess Vaccines for COVID-19: tinyurl.com/2tfn5pme

ICER #WeeklyView: NCFB public meeting, GLP-1s lower costs, & pharma responses to new regulations conta.cc/3IIbHe7

ICER #WeeklyView: CMS report, GLP-1 cost-effectiveness, & soaring health care costs conta.cc/4mjUh59

Institute for Clinical and Economic Review to Undertake Special Report on Crohn’s Disease and Ulcerative Colitis for CMS as Part of Public Comment Process on Medicare Drug Price Negotiations: tinyurl.com/4urn4xf7

ICER #WeeklyView: Obesity draft evidence report, NCFB evidence report, & a crackdown on pharma ads conta.cc/46wGALw

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatments for Obesity: tinyurl.com/4zzsd7dw

Institute for Clinical and Economic Review Publishes Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/39by2hs5

ICER #WeeklyView: SMA final evidence report, upcoming GLP-1 draft report & prescription drug reforms conta.cc/3V0BdOo

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatments for Spinal Muscular Atrophy: tinyurl.com/mw453b9h

ICER #WeeklyView: A note from ICER’s CEO, rising employer health costs, & direct-to-consumer pricing conta.cc/4mV72nD

The Health Economics Methods Advisory (HEMA) has a new website! hemamethods.org HEMA was convened by leaders at 3 global HTA organizations: ICER, @nicecomms.bsky.social, and @cda-amc.bsky.social to critically and independently examine and assess new methods and processes.

The first HEMA Draft Report will be published on September 24th, which will be open to public comment until October 15th. Mark your calendars and submit your public comments via [email protected]! Learn more: hemamethods.org

ICER #WeeklyView: reflections on new GLP-1 research, an NCFB approval, & the impact of rising premiums conta.cc/3UtEllG

ICER #WeeklyView: ICER’s Patient Council, RFK Jr. cancels $500M mRNA vaccine contracts, & CMMI to experiment with weight loss Rx coverage: conta.cc/451WXiC

New @healthaffairs.bsky.social paper on how CMS can integrate formal aspects of #HTA, much of which is patterned after @icer-review.bsky.social practices! Many thanks to @commonwealthfund.org for their support. @basucally.bsky.social @leah-rand.bsky.social www.healthaffairs.org/doi/10.1377/...

TODAY -- at 11 AM ET join us for the virtual public meeting on the comparative clinical effectiveness and value of several treatments for spinal muscular atrophy (SMA). Register here: events.zoom.us/ev/AoeC1QxiP...

ICER #WeeklyView: Today’s SMA public meeting, more on MFN, & the Sarepta controversy continues conta.cc/3UC8zmm

Institute for Clinical and Economic Review to Assess Therapies for IgA Nephropathy: tinyurl.com/3z3pv8rz

This Friday -- at 11 AM ET join us for the virtual public meeting on the comparative clinical effectiveness and value of several treatments for spinal muscular atrophy (SMA). Register here: events.zoom.us/ev/AoeC1QxiP...

ICER #WeeklyView: NCFB Draft Evidence Report, Sarepta vs FDA, & Makary’s new voucher program conta.cc/41aqUKX

Institute for Clinical and Economic Review Releases Draft Evidence Report on Treatment for Non-Cystic Fibrosis Bronchiectasis: tinyurl.com/y65ncwez

ICER #WeeklyView: A “Prescription for Better Access” episode, SMA Evidence Report, & Final MS Report conta.cc/3IPogE0

Institute for Clinical and Economic Review Publishes Evidence Report on Treatments for Spinal Muscular Atrophy: icer.org/news-insight...

Institute for Clinical and Economic Review Publishes Final Evidence Report on Treatment for Secondary Progressive Multiple Sclerosis: icer.org/news-insight...

ICER #WeeklyView: ICER’s iterative approach, a vaccine lawsuit against RFK Jr, & the Supreme Court passes on PBMs conta.cc/3GFNmVf